Table 1.
Patient clinical characteristics at presentation.
| Characteristic | No. of patients |
|---|---|
| Age, > 60 | 21 (42%) |
| Sex, male | 27 (54%) |
| Performance status, ECOG >1 | 3 (6%) |
| B-symptoms at presentation | 12 (24%) |
| Involvement site features | |
| Confined to colon | 10 (20%) |
| Colon & regional LNs | 16 (32%) |
| Colon & intra-abdominal distant LNs | 10(20%) |
| Colon & extra-abdominal LNs | 4 (8%) |
| Disseminated spread to extra-nodal sites† | 10 (20%) |
| Colon involvement sites | |
| Ileocecal lesion* | 46 (92%) |
| Non-ileocecal lesion | 4 (8%) |
| Ann Arbor stage | |
| I–II | 36 (72%) |
| III–IV | 14 (28%) |
| LDH > upper normal range | 19 (38%) |
| IPI | |
| Low or low-intermediate risk | 39 (78%) |
| Intermediate-high or high risk | 11 (22%) |
| Front-line treatment | |
| Resection only | 1 (2%) |
| R-CHOP #1-4 | 1 (2%) |
| R-CHOP #5-8 | 11 (22%) |
| Resection + R-CHOP #1-4 | 4 (8%) |
| Resection + R-CHOP #5-8 | 33 (66%) |
ECOG, Eastern Cooperative Group; LN, lymph node; LDH, lactate dehydrogenase; IPI, International Prognostic Index; R-CHOP, rituximab-cyclophosphamide-hydroxydaunorubicin-vincristine-prednisone; †, Extra-nodal sites included other colon, peritoneum, liver, and bone marrow.
*4 cases also included non-ileocecal lesions.